Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))

研究成果: 雜誌貢獻評論/辯論同行評審

摘要

The authors regret that the information of the second corresponding author (M.-C. Chen) in the affiliation was misplaced. The correct version should be: Mei-Chuan Chena,b,h ∗∗ b Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taiwan. The authors would like to apologise for any inconvenience caused.
原文英語
文章編號112404
期刊European Journal of Medicinal Chemistry
201
DOIs
出版狀態已發佈 - 九月 1 2020

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

指紋 深入研究「Corrigendum to“Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo”[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086] (European Journal of Medicinal Chemistry (2020) 190, (S0223523420300532), (10.1016/j.ejmech.2020.112086))」主題。共同形成了獨特的指紋。

引用此